M. Deininger

发表

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy

D. Niederwieser, H. Al-Ali, R. Krahl, 2004 .

Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.

L. Campbell, A. Green, A. Bench, 2002, Blood.

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome‐negative cells

M. Baccarani, H. Kantarjian, B. Druker, 2007, Cancer.

Does the P 2 X 1 del variant lacking 17 amino acids in its extracellular domain represent a relevant functional ion channel in platelets ?

L. Campbell, A. Green, D. Niederwieser, 2002 .

Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens

D. Niederwieser, M. Herold, R. Krahl, 2001, Bone Marrow Transplantation.

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

B. Druker, M. Heinrich, D. Niederwieser, 2004, The hematology journal : the official journal of the European Haematology Association.

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

D. Niederwieser, H. Al-Ali, R. Krahl, 2003, Blood.

No evidence for persistence of BCR-ABL-positive cells in patients in molecular remission after conventional allogenic transplantation for chronic myeloid leukemia.

D. Niederwieser, A. Chase, R. Krahl, 2000, Blood.

The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients.

D. Niederwieser, R. Krahl, Christel Müller, 2002, Cancer genetics and cytogenetics.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

G. Superti-Furga, O. Hantschel, I. Kaupe, 2010, Blood.

Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative hlaidentical sibling ALLOGRAFTS

R. Storb, B. Sandmaier, D. Maloney, 2000 .

Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms.

J. Prchal, M. Y. Lim, C. Parker, 2021, Blood Coagulation and Fibrinolysis.

CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall.

D. Niederwieser, E. Hennig, S. Leiblein, 2002, Blood.

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

D. Niederwieser, C. Junghanss, M. Cross, 2020, Leukemia & lymphoma.

Deletions of the derivative chromosome 9 do not account for the poor prognosis associated with Philadelphia-positive acute lymphoblastic leukemia.

L. Campbell, A. Green, D. Niederwieser, 2002, Blood.

The molecular biology of chronic myeloid leukemia.

J. Melo, M. Deininger, J. Goldman, 2000, Blood.

FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

U. Reinhold, D. Niederwieser, M. Deininger, 2003, Leukemia.

BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning

R. Brand, D. Niederwieser, U. Hegenbart, 2004, Leukemia.

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

P. Paschka, D. Hossfeld, H. Gschaidmeier, 2003, Leukemia.

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

D. Niederwieser, M. Cross, H. Al-Ali, 2008, Leukemia.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

D. Niederwieser, H. Al-Ali, R. Krahl, 2004, Haematologica.